Xenon to Report Q3 2025 Financial Results on November 3, 2025
Rhea-AI Summary
Xenon Pharmaceuticals (Nasdaq: XENE) will report third quarter 2025 financial results and provide a business update after U.S. market close on Monday, November 3, 2025 at 4:30 PM ET (1:30 PM PT). A live webcast and replay will be available on Xenon’s investors website; dial-in details and conference ID are provided for callers.
The company is a neuroscience-focused biopharmaceutical developer; its lead molecule azetukalner is in Phase 3 trials for epilepsy, major depressive disorder and bipolar depression, and Xenon also has Phase 1 Kv7 and Nav1.7 pain programs.
Positive
- None.
Negative
- None.
News Market Reaction 4 Alerts
On the day this news was published, XENE gained 2.77%, reflecting a moderate positive market reaction. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $90M to the company's valuation, bringing the market cap to $3.34B at that time.
Data tracked by StockTitan Argus on the day of publication.
VANCOUVER, British Columbia and BOSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced it will report its third quarter 2025 financial results and provide a business update after the close of U.S. financial markets on Monday, November 3, 2025.
Conference Call/Webcast Information:
| Date: | Monday, November 3, 2025 |
| Time: | 4:30 pm Eastern Time (1:30 pm Pacific Time) |
| Webcast: | Pre-register here |
| Dial-In: | (800) 715-9871 toll-free or (646) 307-1963 for international callers |
| Conference ID: | 3971394 |
A live webcast of the company presentation will be available on the Investors section of Xenon’s website and posted for replay following the event. The above listed dates and times are subject to change.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. Xenon’s lead molecule, azetukalner, is a novel, potent, selective Kv7 potassium channel opener in Phase 3 clinical trials for the treatment of epilepsy, major depressive disorder (MDD) and bipolar depression (BPD). Xenon is also advancing an early-stage portfolio of multiple promising potassium and sodium channel modulators, including Kv7 and Nav1.7 programs in Phase 1 development for the potential treatment of pain. Xenon has offices in Vancouver, British Columbia, and Boston, Massachusetts. For more information, visit www.xenon-pharma.com and follow us on LinkedIn and X.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Contact:
Colleen Alabiso
Senior Vice President, Corporate Affairs
(617) 671-9238
Media: media@xenon-pharma.com
Investors: investors@xenon-pharma.com
FAQ
When will Xenon (XENE) report Q3 2025 results and provide a business update?
How can investors access Xenon (XENE) Q3 2025 webcast and replay?
What are the dial-in details for Xenon (XENE) November 3, 2025 conference call?
What clinical programs will Xenon (XENE) likely discuss in the Q3 2025 update?
Where can media and investors contact Xenon (XENE) for more information ahead of the Q3 2025 call?
